Introduction
============

COPD is a global health issue.[@b1-copd-13-2163]--[@b3-copd-13-2163] Academia and industry responded with the development of various inhaled therapeutics, but a plateau in treatment effect seems to have been reached.[@b4-copd-13-2163] Therapeutic procedures that provide durable improvements in COPD patients are rare, but they are a next logical bridge in the treatment of this chronic and progressive disease. However, just as with pharmaceuticals, early safety evaluation of devices must first be undertaken to understand long-term effects prior to moving into larger efficacy clinical trials.

Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD that is intended to achieve bronchodilation via ablation of parasympathetic pulmonary nerves entering the lung and running along the outside of the two main bronchi. An earlier study established a reasonable safety profile when treating both lungs in a staged fashion.[@b5-copd-13-2163] The current study was specifically designed to understand the safety profile when completing TLD treatment in both lungs when performed as a single procedure. Investigators hypothesized that this would be the preferred way to treat in the future and would result in added safety over treatment staging, mainly due to reduced exposure to anesthesia and reduced risk of exacerbations induced by bronchoscopy. Furthermore, the current study provides 3-year follow-up data in treated patients to provide early information on potential long-term effects of TLD.

Patients and methods
====================

Study design
------------

This nonrandomized, prospective single-dose registry study was conducted at four sites in Austria (1 site) and France (3 sites) between September 6, 2012 and May 5, 2015. This design was identical to the previous study[@b5-copd-13-2163] except that TLD therapy was delivered to both lungs during a single procedure (vs staged), a single power (vs two) was investigated, and additional bronchoscopic and computed tomography (CT) assessments at 365 days were conducted to assess safety. Sites did not overlap with the previous published first-in-human study, which helped to strengthen the safety assessment and gain additional user information for device development.

Study participants
------------------

Major entry criteria were identical to the first-in-human study and are listed in [Table 1](#t1-copd-13-2163){ref-type="table"}. Follow-up bronchoscopy and CT scans were performed to evaluate the longer-term safety of treatment areas.

Study oversight
---------------

This study was approved by the ethics committee of the City of Vienna (reference: EC 11-251-0112) and the institutional review board (IRB) of South East V, University Hospital Center Grenoble (France), Committee for patient protection (reference: 2012-A00728-35) and was conducted according to the Declaration of Helsinki (1996), Good Clinical Practice guidelines, and local requirements. Operations and a data-monitoring committee oversaw protocol management and safety for the study. An independent clinical event reviewer adjudicated all reported serious adverse events (SAEs). All participating subjects provided written informed consent.

Procedures
----------

Analysis included spirometry, body plethysmography, cycle ergometry, 6-min walk test (6MWT), COPD-specific St George's Respiratory Questionnaire (SGRQ, score range 0--100 with a minimally clinically important difference of ≥4 negative units),[@b6-copd-13-2163] the Clinical SGRQ-C (COPD) (7-day version, score range 0--6, with an minimally clinically important difference of 0.4 units),[@b7-copd-13-2163] and the common Borg and modified Medical Research Council[@b8-copd-13-2163] scales. All appropriate permissions to use validated questionnaires were obtained by the study sponsor. Cycle ergometry was first conducted as an incremental maximal test to determine the baseline maximum work rate (W~max~) off drugs and subsequently as an endurance test conducted at a constant work rate of 75% of the W~max~.[@b9-copd-13-2163] The current American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines were followed for pulmonary function test (PFT);[@b10-copd-13-2163],[@b11-copd-13-2163] however, due to the feasibility nature of the study, no prospective PFT quality oversight program was implemented. ATS/American College of Chest Physicians (ACCPs) and ATS guidelines were followed for cycle ergometry[@b12-copd-13-2163] and the 6MWT,[@b13-copd-13-2163] respectively. Chest CT scan was required to confirm appropriate bronchial anatomy and rule out other pulmonary abnormalities prior to treatment and to evaluate bronchial and peri-bronchial effects following treatment.

Following informed consent, patients underwent "washout" baseline analysis after a washout period of 8 days for long-acting muscarinic antagonists (LAMAs), 24 h for long-acting beta agonist (LABA), and 12 h for short-acting beta agonist (SABA) and short-acting muscarinic antagonist (SAMA). Patients were then asked to take tiotropium bromide, and after a minimum of an 8-day run-in period similar analysis was performed on drug trough 24 h after the last dose of tiotropium to establish "tiotropium trough" baseline values. LABAs were again withheld for 24 h and SABAs and SAMAs for 12 h prior to this analysis if taken. Post-treatment, subjects were asked to remain off tiotropium. Similar to the abovementioned information, any COPD medications taken by the patient must have been appropriately washed out (based on half-life of the drug) prior to the follow-up analysis visits. Paper diaries were utilized by the site study coordinators to help manage medications prior to analysis. Detailed medication utilization was not tracked as part of this feasibility study.

All patients underwent early safety evaluation by phone at 3 and 10 days post-procedure and analysis at washout baseline, tiotropium trough baseline, and 30, 90, 180, 270, and 365 days, and then 1.5, 2, 2.5, and 3 years post-treatment if reconsented for longer-term follow-up. Exceptions to the analysis schedule was cycle ergometry that was performed only at washout baseline, 90, 180, and 365 days, and 2 years following treatment; bronchoscopy was performed at treatment and 90 and 365 days post-procedure; CT scan was performed at washout and 365 days after treatment.

TLD
---

TLD was delivered via a dual cooled radiofrequency (RF) generator system ([Figure 1](#f1-copd-13-2163){ref-type="fig"}) and has been previously described.[@b5-copd-13-2163]

As RF current is delivered through the airway and surrounding tissues, these tissues are heated and the nerves are ablated. Simultaneous cooling removes heat from the inner surface of the bronchi. The net effect is the targeted tissue ablation at depth with minimal heating and damage of the inner surface of the airway. The goal of targeted ablation is to disrupt motor axons within bronchial nerve branches running along the main bronchi, thereby blocking parasympathetic signaling to the lungs and decreasing neuronal release of acetylcholine ([Figure 2](#f2-copd-13-2163){ref-type="fig"}).

TLD was performed under general anesthesia via rigid bronchoscopy due to the dimensions of this first-generation catheter. The study was designed to assess the safety of bilateral lung treatment during a single procedure; however, a procedure could be staged per physician discretion. The electrode was placed and activated as prescribed in up to eight rotational positions per bronchus to achieve a complete circumferential treatment. Bronchoscopic and fluoroscopic visualization was used to guide in electrode positioning. Energy-level determination came from extensive preclinical analysis and early safety outcomes from the first-in-human study.[@b5-copd-13-2163] Subjects were asked to stop taking tiotropium after the completion of the procedure.

Study end points
----------------

The primary safety end point of freedom from documented and sustained worsening of COPD directly attributable to the investigational device or procedure to 365 days post-TLD therapy was defined as a decrease in the individual patient's forced expiratory volume in 1 s (FEV~1~) by any amount at all follow-up time points along with a report of an adverse event that was reported to have a probable or definite relation to the device. Secondary end points included technical feasibility of the device, change in PFTs, exercise capacity assessments, and health-related quality of life. Technical feasibility was defined as the ability to access the target treatment area in the main bronchus and deliver RF energy to the entire circumference of the bronchus at the target treatment sites.

Statistical analyses
--------------------

There was no primary study hypothesis with statistical inference for the small registry study. All *p*-values were presented for informational purposes. According to the prespecified analysis plan, continuous data were summarized using mean and SD, or medians and quartiles in the presence of non-normality. Categorical data were tabulated with counts and percentages. All the available data were summarized with no imputation for missing data. Final analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) by an independent statistical group (NAMSA, Minneapolis, MN, USA).

Results
=======

Baseline characteristics for the 15 patients treated are shown in [Table 2](#t2-copd-13-2163){ref-type="table"}. Patient disposition throughout 3 years is shown in [Figure 3](#f3-copd-13-2163){ref-type="fig"}. Follow-up data beyond 365 days were available for 67% (n=10) at 2 years and 60% (n=9) at 3 years. Three patients did not participate in follow-up beyond 1 year and refused or withdrew consent, with one withdrawing due to planned bladder surgeries. Later study exits were due to physician discretion and relocation.

Technical success of TLD treatment was achieved in 93% of cases, with one patient receiving treatment in seven of eight expected quadrants due to poor balloon contact. No device-related adverse events during the procedure were reported. All 15 patients underwent treatment at an energy level of 15 W. A staged procedure was performed in a total of two patients due to the airway size being unexpectedly larger than the balloon available at the time of the initial treatment.

Safety
------

The primary safety end point, defined as freedom from documented and sustained worsening of COPD directly attributable to the investigational device or procedure to 365 days post-TLD therapy, was achieved in 100% (15/15) of patients. No significant wall effects (ie, ulcers and narrowing) were observed during this study at either the 90-day or 365-day follow-up bronchoscopy and CT assessments ([Figure 4](#f4-copd-13-2163){ref-type="fig"}).

No device-related adverse events were reported. No deaths occurred in the entire 3-year follow-up period. A total of 12 SAEs were reported during the follow-up consisting of five COPD exacerbations (occurring at 3 months, 1 year, 1.5 years, and 2 at 2 years), one urinary retention (with difficult Foley catheter placement and sequela of benign prostatic hypertrophy) occurring 30 days post-treatment, one worsening of an underlying arrhythmia 85 days post-treatment, one hemoptysis (negative bronchoscopy and suspected epistaxis), one motorcycle accident at 24 months, one transient ischemic attack between 2 and 3 years post-treatment, and one nonfatal stroke between 2 and 3 years ([Table 3](#t3-copd-13-2163){ref-type="table"}).

Lung function, exercise capacity, and quality of life
-----------------------------------------------------

To understand the impact of TLD alone on efficacy measures, all follow-up tests were performed while washed out of all bronchodilators, if taken, as previously described. There were statistically significant improvements in lung function and exercise capacity at 365 days post-TLD treatment ([Table 4](#t4-copd-13-2163){ref-type="table"}).

Improvements observed for percent relative change compared with washout baseline of FEV~1~ were significant at all follow-up time points throughout 365 days and for forced vital capacity (FVC) at 30 (*p*=0.017), 180 (*p*=0.016), and 365 days (*p*=0.024; [Figure 5](#f5-copd-13-2163){ref-type="fig"}). Changes in 6MWT reached statistical significance at 90 (*p*=0.015) and 365 days (*p*=0.014) post-TLD treatment. No statistical significance was noted in SGRQ-C changes. Despite numerically higher FEV~1~ and FVC values at 2 and 3 years, statistical significance was lost for parameters of lung function and exercise capacity at these longer follow-up visits.

Discussion
==========

Bilateral TLD therapy performed in a single session in this study demonstrated acceptable peri- and post-procedural safety up to 3 years.

Interruption of vagal innervation to the lung may diminish acetylcholine release from these nerves, which in turn has an influence on airway smooth muscle tone, mucus secretion, and/or local inflammatory processes throughout the bronchial tree.[@b14-copd-13-2163] Indeed, pharmacologic blockade of vagal innervation has been shown to produce sustained bronchodilation and a decrease in mucus production.[@b15-copd-13-2163] An alternative, yet high risk, path of vagal denervation would be surgical resection of the airway nerve trunks of the vagus nerves in human subjects, which according to previous reports led to significant lung function improvements in patients with chronic airflow obstruction.[@b16-copd-13-2163]--[@b18-copd-13-2163] TLD is a novel bronchoscopic therapy that, using a minimally invasive approach, ablates the parasympathetic innervation of the lungs and has a similar proposed mechanism of action to surgical denervation, albeit with the potential of lower morbidity and mortality.[@b19-copd-13-2163] TLD therapy ablates airway nerve trunks using predetermined RF energy while minimizing damage to tissues of the main bronchi through the use of a dual cooling method. We have previously reported results from the first-in-human feasibility and safety study of TLD using a sequential, bilateral treatment approach. In that report, TLD was associated with a higher SAE rate of 1.4 events per patient (31 SAEs in 22 patients) up to a follow-up of 1 year. In the current study, patients with similar baseline characteristics experienced an average 3-year SAE rate of 0.26 per patient/year (12 SAEs in 15 patients), which may indicate improved safety by utilizing the bilateral approach and lower delivered energy as well as advancements in overall procedural training over time.[@b5-copd-13-2163] In fact, in the current study, the procedure was consistently modified to more distal electrode placement away from the thin and thermally sensitive main carina, more detailed visual assessment of balloon contact before activation, and a decrease in overall power to 15 W to further reduce the potential for undesired airway wall effects. In this context, the overall low rate of severe COPD exacerbations during the follow-up period of up to 3 years appears noteworthy. In the absence of a control group, we cannot rule out that this observation is due to a recruitment bias rather than the above-discussed anticholinergic pleiotropic effects, which may influence exacerbation rates similar to pharmacological acetylcholine blockade. Furthermore, given the potential impact of vagotomy on cardiovascular autonomic tone,[@b20-copd-13-2163] it should be noted that there was no evidence of an increased risk of cardiac events associated with the TLD procedure in the current study.

Noteworthy, lung function improvements after TLD therapy at 1 year observed in the current study were of similar magnitude to results from the high-energy cohort (20 W) but higher than the low-energy cohort (15 W) in our previous study.[@b5-copd-13-2163] The latter observation may be explained by an overall higher peak reversibility response to ipratropium on FEV~1~ at baseline in the current study cohort (38%) compared with a reversibility peak relative change in FEV~1~ between 20% and 26% in the previous study. This selection bias may further explain the relatively large magnitude of tiotropium effect during the washout and run-in analysis procedures observed. While the predictive ability of the acute bronchodilator response to long-term inhaled anticholinergic therapy is limited, our observation may indicate a relationship between the response to inhaled short-acting anticholinergic therapy and effects of permanent vagal denervation using TLD therapy. We should acknowledge, however, that the absence of acute bronchodilator response at one occasion may not preclude the demonstration of bronchodilator response on another occasion,[@b21-copd-13-2163] thus limiting the overall usefulness of this criterion for future patient selection for TLD therapy. Another potential explanation for the differences in outcomes between the 15 W cohorts is the lower rates of SAEs observed in the current manuscript compared with our previous work, which may have contributed to an overall better treatment response in the absence of clinical events compromising potential benefits of TLD.

The current study furthermore demonstrated sustained effects of TLD therapy on FEV~1~ and FVC up to 3 years compared with baseline. In addition to the bronchodilator effect that is expected by reducing the release of acetylcholine from the parasympathetic nerves, a previous inflammatory marker study has also provided evidence of potentially inhibiting inflammation and mucus gene expression with TLD therapy.[@b22-copd-13-2163] This finding is consistent with other studies that indicate anti-inflammatory effects of inhaled anticholinergic therapy.[@b23-copd-13-2163],[@b24-copd-13-2163]

While the improvements in lung function were in part accompanied by benefits in exercise capacity, they did not translate into consistent benefits of health-related quality of life in this study. There are a number of potential explanations for this observation as well as other limitations to this report. First, the small sample size likely leads to variability across the time points assessed and not all patients continued follow-up beyond 365 days when the study was extended. Second, it has to be acknowledged that there is a rather modest relationship between treatment-related improvements in FEV~1~ and health-related quality of life.[@b25-copd-13-2163] On the other hand, we have to acknowledge that in the absence of a control group undergoing a sham treatment and the lack of direct measurements of therapeutic efficacy of TLD, such as histological proof of denervation in vivo, improvements in lung function and exercise capacity observed in the current study may have been an intervention effect, rather than a result of the intended mechanism of action. Given the magnitude of response with respect to the FEV~1~ demonstrated in this study and a strict inhaler washout procedure prior to lung function measurements, however, there is a high likelihood of an independent treatment effect.

With long-term safety of TLD being established between two studies now, focus will be on optimizing the energy dose, further refining the procedure, studying potentially additive effects of TLD on top of LAMA treatment, and conducting careful patient phenotyping analysis to identify those patients most likely to benefit from this novel therapy. Since study completion, the manufacturer has made significant device enhancements which allow replacement of rigid bronchoscopy with flexible endoscopy and is currently conducting a randomized, sham control dose and patient selection optimization study.

Conclusion
==========

This intervention study adds to the early body of evidence confirming the feasibility and safety of TLD in patients with symptomatic moderate-to-severe COPD.
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![First generation targeted lung denervation system.\
**Abbreviation:** RF, radiofrequency.](copd-13-2163Fig1){#f1-copd-13-2163}

![Representative ablation procedure.\
**Notes:** (**A**) Image of a representative ablation. The catheter is in left bronchus with electrode in the lateral position. Catheter is rotationally repositioned to achieve complete circumferential treatment. Both the catheter and electrode are filled with cooled fluid to protect the airway inner surface during ablation. (**B**) Blue lines designate the area of circumferential ablation in main bronchi. Attenuation of nerve fibers along the outside of the airway is represented by change in color.](copd-13-2163Fig2){#f2-copd-13-2163}

![Subject disposition.\
**Note:** \*Patients asked to consent for additional follow-up at the 1-year visit.](copd-13-2163Fig3){#f3-copd-13-2163}

![Example of acute and follow-up CT and airway safety inspections.\
**Abbreviation:** CT, computed tomography.](copd-13-2163Fig4){#f4-copd-13-2163}

![Secondary efficacy end points.\
**Notes:** Yellow line represents timing of TLD procedure. Data are represented as mean. Error bars represent SEM. All measures compared with washout baseline analysis. \**p*\<0.05 compared with baseline.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; SEM, standard error of the mean; TLD, targeted lung denervation.](copd-13-2163Fig5){#f5-copd-13-2163}

###### 

Protocol's inclusion and exclusion criteria

  Patient selection criteria
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Inclusion criteria**
  • Post-bronchodilator FEV~1~ 30%--60%
  • Patient is diagnosed with COPD (post-bronchodilator FEV~1~/FVC\<0.7)
  • Positive relative change in FEV~1~ of \>15% following the administration of ipratropium (MDI with four puffs at 20 µg)
  • Age ≥40 years
  • Smoking history of at least 10 pack-years
  • Nonsmoking for a minimum of 6 months prior to consent and agreed to continue not smoking for the duration of the study
  • Patient has provided written informed consent
  • The patient is willing, able, and agreed to complete all protocols required for baseline and follow-up assessments including taking and abstaining from medications
  • The patient has no child-bearing potential or a negative pregnancy test
  • Patient is a candidate for bronchoscopy in the opinion of the physician or per hospital guidelines
  • Current influenza vaccination and/or pneumococcus vaccination consistent with local recommendations and/or policy
  **Exclusion criteria**
  • Pulmonary hypertension, peripheral edema suggesting CHF or polycythemia
  • Patient has an SaO~2~≤88% or a PaO~2~≤7.3 kPa (55 mmHg)
  • Patient has a PaCO~2~\>8.0 kPa (60 mmHg)
  • Prior lung transplant, LVRS, median sternotomy, bullectomy, or lobectomy
  • Pulmonary nodule requiring surgery
  • History of recurrent respiratory infections (\>3 hospitalizations within 1 year of consent)
  • Presence of a pacemaker, internal defibrillator, or other implantable electronic devices
  • Active respiratory infection within the past 4 weeks
  • COPD exacerbation within the past 4 weeks
  • Myocardial infarction within the past 6 months
  • Unstable or life-threatening arrhythmia within the past year
  • Malignancy treated with radiation or chemotherapy within the past 2 years
  • Presence of other respiratory diseases (cystic fibrosis, tuberculosis, vocal cord dysfunction, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis)
  • Known hypersensitivity to anticholinergic drugs or components
  • Known allergy to medications required for bronchoscopy (such as lidocaine and atropine) that cannot be medically controlled
  • Clinical diagnosis of sleep apnea
  • Clinical diagnosis of asthma or other respiratory disease other than COPD
  • Known coagulopathy
  • Patient is taking clopidogrel, coumadin, or other blood-thinning medication
  • The patient has any disease or condition that might interfere with completion of this study (eg, life expectancy \<1 year)
  • Patient is currently enrolled in another clinical trial

**Abbreviations:** CHF, congestive heart failure; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; LVRS, lung volume reduction surgery; MDI, metered-dose inhaler; PaCO~2~, partial pressure of carbon dioxide; PaO~2~, partial pressure of oxygen; SaO~2~, saturation of oxygen.

###### 

Baseline characteristics

  Characteristics                                                                             n=15
  ------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Age (years)                                                                                 63.20 (3.97)
  Male, n (%)                                                                                 7 (47)
  Ethnic origin, n (%)                                                                        
   White                                                                                      15 (100)
  History of smoking, n (%)                                                                   15 (100)
  Pack-years                                                                                  39.4 (6.16)
  Washout pre-bronchodilator FEV~1~ (L)                                                       0.77 (0.24)[\*](#tfn3-copd-13-2163){ref-type="table-fn"}
  Washout pre-bronchodilator FEV~1~ (%)                                                       28.6 (10.9)[\*](#tfn3-copd-13-2163){ref-type="table-fn"}
  Washout pre-bronchodilator FVC (L)                                                          2.25 (0.61)[\*](#tfn3-copd-13-2163){ref-type="table-fn"}
  Reversibility peak relative change in FEV~1~ (%)                                            38.01 (20.18)
  Run-in tiotropium trough, FEV~1~ (L)                                                        1.09 (0.22)
  Run-in tiotropium trough, FVC (L)                                                           2.70 (0.73)
  Average diameter: right main bronchus (mm)[\*\*](#tfn4-copd-13-2163){ref-type="table-fn"}   14.10 (2.74)
  Average diameter: left main bronchus (mm)[\*\*](#tfn4-copd-13-2163){ref-type="table-fn"}    13.15 (1.69)

**Notes:** Data are represented as mean (SD) unless stated otherwise.

Post-bronchodilator information not correctly recorded in error.

Measurements by sponsor using Apollo^®^ Software (VIDA Diagnostics, Coralville, IA, USA).

**Abbreviations:** FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

###### 

Summary of adverse events through 3 years

  Adverse event                  ≤30-day events (n=15), n (%)   ≥30 days to 1 year (n=15), n (%)   1--2 years (n=10), n (%)   2--3 years (n=9), n (%)
  ------------------------------ ------------------------------ ---------------------------------- -------------------------- -------------------------
  SAEs                                                                                                                        
   COPD exacerbation                                            2 (13)                             3 (30)                     
   Heart arrhythmia                                             1 (7)                                                         
   Hemoptysis                                                                                      1 (10)                     
   Hypertrophy of prostate       1 (7)                                                                                        
   Motorcycle accident                                                                                                        1 (11)
   Stroke                                                                                                                     2 (22)
   Urinary retention             1 (7)                                                                                        
  Nonserious adverse events                                                                                                   
   Common cold                   1 (7)                                                                                        
   COPD exacerbation             2 (13)                         2 (13)                             11 (110)                   3 (33)
   Cough                                                        1 (7)                                                         
   Dislodged teeth               1 (7)                                                                                        
   Dysphagia                     2 (13)                                                                                       
   Epigastric pain               2 (13)                                                                                       
   Headache                                                                                                                   1 (11)
   Hemoptysis                                                   1 (7)                              1 (10)                     
   Herpes zoster                                                                                   1 (10)                     
   Hoarseness                                                                                                                 1 (11)
   Hypoxemia                     1 (7)                                                                                        
   Lower respiratory infection                                  5 (33)                             1 (10)                     
   Nausea/vomiting                                              1 (7)                                                         
   Paresthesia (left hand)                                                                         1 (10)                     
   Tachycardia                                                                                                                2 (22)
   Tingling in left upper lobe   1 (7)                                                                                        
   Thoracic pain                 1 (7)                                                                                        
   Sigmoiditis                                                  1 (7)                                                         
   Syncope                                                                                                                    1 (11)

**Abbreviation:** SAE, serious adverse event.

###### 

Baseline and outcomes at 365 days

  Lung function test               n=15                                    
  -------------------------------- ------------------- ------------------- ------------------------------------------------------------
  FEV~1~ (mL)                      765.33 (237.45)     1,012.14 (272.99)   40.29 (42.12)[\*](#tfn8-copd-13-2163){ref-type="table-fn"}
  FVC (mL)                         2,248.00 (614.05)   2,605.00 (634.59)   19.25 (24.84)[\*](#tfn8-copd-13-2163){ref-type="table-fn"}
                                                                           
                                   **Baseline**        **365 days**        **Absolute change from baseline**
                                                                           
  Cycle ergometry (min)            7.36 (2.96)         9.81 (4.92)         2.68 (6.06)
  Borg scale: post-cycle dyspnea   5.4 (2.35)          4.64 (1.21)         −0.82 (1.83)
  mMRC                             2.27 (1.03)         1.60 (1.06)         −0.67 (1.05)
  6MWT (m)                         361.8 (125.62)      415.47 (112.76)     53.67 (74.40)[\*](#tfn8-copd-13-2163){ref-type="table-fn"}
  SGRQ: total score                47.95 (16.97)       49.37 (20.93)       −1.85 (20.77)
  CCQ: total score                 2.71 (1.17)         2.63 (1.41)         0.00 (1.29)

**Notes:** Data are represented as mean (SD) unless stated otherwise.

*p*\<0.05 compared with baseline.

**Abbreviations:** CCQ, Clinical COPD Questionnaire; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnea scale; 6MWT, 6-min walk test; SGRQ, St George's Respiratory Questionnaire (COPD specific).
